Affordable Access

Publisher Website

ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.

Authors
  • Chaluts, Danielle1
  • Dullea, Jonathan T2
  • Ali, Muhammad1
  • Vasan, Vikram1
  • Devarajan, Alex1
  • Rutland, John W1
  • Gill, Corey M1
  • Ellis, Ethan3
  • Kinoshita, Yayoi4
  • McBride, Russell B4, 5
  • Bederson, Joshua1
  • Donovan, Michael4
  • Sebra, Robert6, 3
  • Umphlett, Melissa4
  • Shrivastava, Raj K1
  • 1 Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue; Floor 8, New York, NY, 10129, USA.
  • 2 Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue; Floor 8, New York, NY, 10129, USA. [email protected].
  • 3 Sema4, A Mount Sinai Venture, Stamford, CT, USA.
  • 4 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • 5 The Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • 6 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Type
Published Article
Journal
Journal of Cancer Research and Clinical Oncology
Publisher
Springer-Verlag
Publication Date
Jul 01, 2023
Volume
149
Issue
8
Pages
5165–5172
Identifiers
DOI: 10.1007/s00432-022-04442-y
PMID: 36348021
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The oncologic outcomes for atypical meningiomas can be poor. Generally, patients that have had a prior recurrence have a substantially elevated risk of a future recurrence. Additionally, certain tumor genomic profiles have been shown as markers of poor prognosis. We sought to characterize the genomic differences between primary and recurrent tumors as well as assess if those differences had implications on recurrence. We identified primary and recurrent gross totally resected WHO grade II meningiomas with > 30 days of post-surgical follow-up at our institution. For genes with a prevalence of > 5% in the cohort, we compared the mutational prevalence in primary and recurrent tumors. For a gene of interest, we assessed the time to radiographic recurrence using adjusted cox-regression. We identified 88 meningiomas (77 primary, 16 recurrent) with a median follow-up of 5.33 years. Mutations in ARID1A found in association with recurrent tumors (7/16 recurrent tumors vs 5/72 primary tumors, p < 0.001). In the whole cohort, mutations in ARID1A were not associated with alterations in time to recurrence after adjusting for recurrence status (p = 0.713). When restricted to primary tumors, ARID1A is associated with a 625% increase in the hazard of recurrence (HR = 7.26 [1.42-37.0]; p = 0.017). We demonstrate mutations in ARID1A, a chromatin remodeling gene, in a higher prevalence in recurrent tumors. We further demonstrate that when mutations in ARID1A are present in primary atypical meningiomas, these tumors tend to have worse prognosis. Further prospective study may validate ARID1A as a prognostic marker. © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Report this publication

Statistics

Seen <100 times